August 19, 2017 3:01 PM ET

Pharmaceuticals

Company Overview of Novartis Pharmaceuticals Corporation

Company Overview

Novartis Pharmaceuticals Corporation researches, develops, manufactures, and markets medicines and treatments for helping patients and improving patient care. It offers prescription drugs to treat various diseases and conditions, including cancer, cardiovascular, central nervous system, endocrine, inflammatory, ophthalmic, infectious, neurological, organ transplantation, psychiatric, respiratory, skin, and infectious diseases and conditions. The company also provides patient assistance programs to manage diseases and conditions. Novartis Pharmaceuticals Corporation was formerly known as Sandoz Pharmaceuticals Corporation and changed its name to Novartis Pharmaceuticals Corporation in March 1...

One Health Plaza

East Hanover, NJ 07936-1080

United States

Founded in 1968

Phone:

973-781-8300

Fax:

973-781-8265

Key Executives for Novartis Pharmaceuticals Corporation

President, US Country Head and President of Novartis Corporation
Chief Financial & Administrative Officer and Vice President
Chief Compliance Officer, Vice President and Us Country Head of Ethics & Compliance
Vice President, General Counsel and US Country Head of Legal
Vice President of Communications and US Country Head of Communications
Compensation as of Fiscal Year 2017.

Novartis Pharmaceuticals Corporation Key Developments

Novartis Pharmaceuticals Corporation Announce Acceptance of US Food and Drug Administration to Review Biologics License Application (Bla) for AMG 334

Novartis announced that the US Food and Drug Administration has accepted for review the Biologics License Application (BLA) for AMG 334 (erenumab) for the prevention of migraine in patients experiencing four or more migraine days per month. If approved, erenumab is expected to be the first and only fully human monoclonal antibody targeting the calcitonin gene-related peptide receptor, specifically designed for the prevention of migraine. Phase II and Phase III clinical studies of erenumab versus placebo have demonstrated a significant reduction in the number of migraine-affected days, acute medication over-use and disability, while improving quality of life for patients with episodic and chronic migraine. The safety profile of erenumab was similar to placebo in over 2,600 patients in the Phase II and Phase III studies assessing the prevention of migraine, and persistence rates were approximately 90%. AMG 334 (erenumab) is the only fully human monoclonal antibody specifically designed for the prevention of migraine that has been filed with the FDA. Erenumab specifically inhibits the receptor of the calcitonin gene-related peptide (CGRP), which is thought to play a causal role in migraine pathophysiology. Erenumab has been studied in several large global, randomized, double-blind, placebo-controlled trials to assess its safety and efficacy in migraine prevention.

Novartis Pharmaceuticals Corporation Presents at CASSS’ CMC Strategy Forum Summer 2017, Jul-18-2017 12:00 PM

Novartis Pharmaceuticals Corporation Presents at CASSS’ CMC Strategy Forum Summer 2017, Jul-18-2017 12:00 PM. Venue: Gaithersburg, Maryland, United States. Speakers: Cynthia Riggins.

Novartis Pharmaceuticals Presents at St. Petersburg International Economic Forum 2017 Programme, Jun-03-2017 08:30 AM

Novartis Pharmaceuticals Presents at St. Petersburg International Economic Forum 2017 Programme, Jun-03-2017 08:30 AM. Venue: St. Petersburg, Russia. Speakers: Nikolaos Tripodis, Managing Director.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Novartis Pharmaceuticals Corporation, please visit www.pharma.us.novartis.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.